| Literature DB >> 35854219 |
Eunice Magoma Machuka1,2, John Juma3, Anne Wangari Thairu Muigai4, Joshua Oluoch Amimo5, Roger Pelle6, Edward Okoth Abworo3.
Abstract
BACKGROUND: African swine fever (ASF) is a lethal hemorrhagic disease affecting domestic pigs resulting in up to 100% mortality rates caused by the ASF virus (ASFV). The locally-adapted pigs in South-western Kenya have been reported to be resilient to disease and harsh climatic conditions and tolerate ASF; however, the mechanisms by which this tolerance is sustained remain largely unknown. We evaluated the gene expression patterns in spleen tissues of these locally-adapted pigs in response to varying infective doses of ASFV to elucidate the virus-host interaction dynamics.Entities:
Keywords: ASFV; Chemokines; Cytokines; Dual RNA-Seq; Locally-adapted pigs; Spleen; Swine; Vaccine
Mesh:
Substances:
Year: 2022 PMID: 35854219 PMCID: PMC9294756 DOI: 10.1186/s12864-022-08754-8
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 4.547
Fig. 1A survival analysis curve
Mapping statistics to the pig and the ASF virus reference genomes
| Study group | High dose | Medium dose | Low dose | Control |
|---|---|---|---|---|
| Number of biological replicates | 3 | 3 | 3 | 1 |
| Total trimmed reads | 9,660,832 | 12,889,691 | 45,343,542 | 30,355,538 |
| No of reads mapped to pig host | 5,763,796 | 3,493,725 | 42,818,622 | 27,560,673 |
| No of genes mapped to pig host (% of coding genes mapped) | 14,544 (93.56%) | 13,755 (88.5%) | 15,543 (99.99%) | 15,527 (99.88%) |
| No of reads mapped to ASFV pathogen | 14,302 | 13,363 | 12,381 | 0 |
| No of genes mapped to ASFV pathogen (% of coding genes mapped) | 172 (98.86%) | 174 (99.43%) | 167 (95.43%) | 0 |
Fig. 2Mapping rates (A) to the pig and (B) to the ASF virus genomes. Created with Datawrapper on https://www.datawrapper.de/; accessed on 2nd March 2022
Fig. 3DEGs between three dose groups (A) in the pig host and (B) in the ASFV genes, and (C) Volcano plots for DEGs between high dose and control groups of pigs and (D) Volcano plots for DEGs between medium dose and control groups of pigs. (E) Volcano plots for DEGs between low dose and control groups of pigs. The dotted line across the volcano plots shows the cutoff for DEGs > 95% confidence (p < 0.05). (F) A heatmap of the DEGs
List of select pig host genes detected in ASFV-infected pigs. Genes were selected based on function and mean fold change for three dose groups. The highest expressed fold change value between medium and high dose groups was recorded
| Gene | log2 Fold Change | adjusted | Gene Product | Function | Reference |
|---|---|---|---|---|---|
| | − 1.85 | 1.76E-02 | CD163 antigen | A hemoglobin-specific receptor is found on the cell surface of macrophages involved in iron recycling and inflammatory response. | [ |
| | 4.18 | 9.93E-19 | Regulator of G Protein Signaling 16 | Restricts pro-inflammatory response of monocytes | [ |
| | −2.13 | 2.06E-05 | Heme oxygenase-1 | Pro-oxidant and pro-inflammatory effects | [ |
| | 7.03 | 3.01E-09 | Calcyclin | Binds CD68 | [ |
| | 2.11 | 1.29E-02 | Granulocyte colony-stimulating factor (G-CSF) | Involved in proliferation and differentiation of granulocytes | [ |
| | 3.25 | 6.58E-04 | Thrombospondin 1 | Inhibits angiogenesis, regulates antitumor immunity and regulates extracellular proteases and growth factors. | [ |
| | 1.87 | 2.62E-04 | Interferon-induced protein with tetratricopeptide repeats 2 | IFN-induced antiviral protein which inhibits expression of viral messenger RNAs that lack 2′-O-methylation of the 5′ cap | [ |
| | 3.05 | 2.80E-09 | interferon induced transmembrane protein 3 | Engages and shuttles the virus particles to lysosomes for clearance from the cells | [ |
| | 2.59 | 7.49E-05 | GADD34 | Guides dephosphorylation of eIF2a by PP1 | [ |
| | − 6.87 | 2.02E-09 | Spi-C Transcription Factor | Restrains inflammation and iron metabolism in macrophages | [ |
| | 5.73 | 6.21E-15 | Nuclear protein 1 | Suppresses programmed cell death by apoptosis and programmed necrosis | [ |
| | −5.01 | 8.73E-03 | CD244 molecule | Involved in NK cell stimulation and NK cell-mediated cytotoxicity | [ |
| | − 3.05 | 1.06E-12 | Cytoplasmic FMR1 interacting protein 2 | Involved in T-cell adhesion and p53/TP53-dependent induction of apoptosis | [ |
| | 5.67 | 1.50E-26 | Interleukin 6 | Promotes virus survival and exacerbation of clinical disease | [ |
| | −2.39 | 9.44E-06 | Damage-regulated autophagy modulator 2 | Oncogenic regulator: promotes cell metastasis and proliferation in cancer cells | [ |
| | 1.41 | 1.47E-03 | Suppressor of glucose, autophagy associated 1 | Implicated in autophagy | [ |
| | 5.27 | 2.17E-12 | Tissue inhibitor matrix metallopeptidase inhibitor 1 | Promotes tumorigenesis and metastasis of colon cancer and is a potential prognostic indicator for colon cancer | [ |
| | 5.68 | 3.39E-08 | Lactotransferrin | Sequestering iron and antimicrobial activity | [ |
| | − 5.85 | 7.17E-05 | Calcineurin like EF-hand protein 2 | Regulates cell pH by controlling plasma membrane-type Na+/H+ exchange activity; involved in carcinoma progression | [ |
| | 7.55 | 2.94E-11 | FOS like 1, AP-1 transcription factor subunit | Regulators of cell proliferation, differentiation, and transformation | [ |
| | 2.37 | 3.23E-04 | Forkhead box F1 | FOXF1 transcription factor promotes lung regeneration | [ |
| | 7.11 | 2.84E-07 | Protegrin-4 | Antimicrobial peptide | [ |
| | 4.22 | 1.02E-04 | Prostaglandin E synthase | Plays a crucial role in inflammation by converting prostaglandin (PG) H2 to PGE2 | [ |
Differentially expressed cytokines and their receptors. TND = transcript not detected
| Gene group | Gene | Description | Differential expression in High dose | Differential expression in medium dose | Differential expression in Low dose | |||
|---|---|---|---|---|---|---|---|---|
| Log2 Fold change | Adjusted | Log2 Fold change | Adjusted | Log2 Fold change | Adjusted | |||
| Interleukin 6 | 1.50E-26 | 4.76E-11 | TND | TND | ||||
| Interleukin 17B | 1.56 | 2.94E-02 | TND | TND | TND | TND | ||
| Interleukin 16 | TND | TND | −2.08 | 4.17E-03 | TND | TND | ||
| Interleukin 27 | 4.28E-03 | 2.61 | 2.87E-03 | TND | TND | |||
| Interferon omega 6 | −1.62 | 3.22E-02 | TND | TND | TND | TND | ||
| TNF superfamily member 12 | 1.53 | 1.01E-04 | 1.66 | 6.77E-05 | TND | TND | ||
| TNF superfamily member 13 | TND | TND | 1.63 | 3.63E-03 | TND | TND | ||
| Heparin binding EGF like growth factor | 1.83 | 4.07E-03 | 1.76 | 9.45E-03 | TND | TND | ||
| Vascular endothelial growth factor A | 1.66E-13 | 2.83 | 1.12E-06 | TND | TND | |||
| Interleukin 1 receptor like 1 | 1.11E-09 | 2.58E-07 | TND | TND | ||||
| Interleukin 10 receptor subunit alpha | −1.32 | 1.64E-03 | −2.27 | 1.49E-06 | TND | TND | ||
| interleukin 15 receptor subunit alpha | 1.54 | 4.86E-02 | TND | TND | TND | TND | ||
| Interleukin 17 receptor E like | 1.64 | 2.14E-02 | TND | TND | TND | TND | ||
| Interleukin 21 receptor | −2.61 | 1.44E-06 | −2.78 | 3.62E-05 | TND | TND | ||
| Interleukin 27 receptor subunit alpha | TND | TND | −1.48 | 4.36E-03 | TND | TND | ||
| Interleukin 31 receptor A | −2.31 | 3.59E-03 | 5.42E-03 | TND | TND | |||
| TNF receptor superfamily member 11a | 5.45E-04 | −2.05 | 1.24E-02 | TND | TND | |||
| TNF receptor associated factor 7 | 1.59 | 4.75E-05 | TND | TND | TND | TND | ||
| TNF receptor superfamily member 13B | 2.34 | 8.13E-07 | TND | TND | TND | TND | ||
| TNF receptor superfamily member 18 | 1.99 | 3.68E-03 | TND | TND | TND | TND | ||
| TNF receptor superfamily member 9 | −1.70 | 3.90E-02 | 9.69E-03 | TND | TND | |||
| TNF receptor superfamily member 21 | −1.92 | 1.19E-03 | −1.42 | 2.09E-02 | TND | TND | ||
| TNF receptor superfamily member 13C | TND | TND | −2.33 | 7.88E-03 | TND | TND | ||
| Interleukin 1 receptor associated kinase 1 | 1.73 | 2.26E-06 | TND | TND | TND | TND | ||
| Interleukin 1 receptor associated kinase 3 | −0.87 | 3.75E-02 | TND | TND | TND | TND | ||
| Interleukin 1 receptor associated kinase 4 | −1.22 | 1.67E-02 | TND | TND | TND | TND | ||
Differentially expressed chemokines and their chemotactic activities. TND = transcript not detected
| Chemokine | Key immune function | Differential expression in High dose | Differential expression in medium dose | Differential expression in Low dose | Chemotactic activity | |||
|---|---|---|---|---|---|---|---|---|
| log2 Fold Change | padj | log2 Fold Change | padj | log2 Fold Change | padj | |||
| Inflammatory monocyte trafficking | 4.03 | 3.76E-10 | 4.11 | 1.12E-08 | TND | TND | Classical monocyte, Natural killer cells | |
| Macrophage and natural killer cell migration; T cell–dendritic cell interactions | 1.69 | 2.30E-02 | TND | TND | TND | TND | Nonclassical-Monocyte, Natural killer cells | |
| T cell and dendritic cell homing to lymph node | TND | TND | −4.30 | 6.14E-04 | Neutrophils, CD8+ T cells, dendritic cells | |||
| Eosinophil and basophil migration | −5.28 | 2.51E-04 | −4.17 | 3.45E-03 | TND | TND | Th2 type T lymphocytes | |
| Neutrophil trafficking | 3.44 | 9.55E-06 | 2.68 | 1.70E-03 | TND | TND | Neutrophils, CD8+ T cells, monocytes/macrophage, natural killer cells | |
| Neutrophil trafficking | TND | TND | 2.42 | 1.22E-02 | TND | TND | Neutrophils, CD8+ effector T cells, monocytes/macrophage, natural killer cells | |
| Th1 response; Th1, CD8, NK trafficking | 1.62 | 8.29E-03 | 2.85 | 4.93E-05 | −2.56 | 1.61E-03 | CD8+ T cells, T helper cells (Th1), natural killer cells | |
| B cell and follicular helper (Tfh) cell positioning in lymph node | −2.52 | 2.35E-03 | −1.67 | 4.13E-02 | TND | TND | B cells | |
Differentially expressed genes involved in MHC antigen processing and presentation. TND = transcript not detected
| Gene | Description | Differential expression in High dose | Differential expression in medium dose | Differential expression in Low dose | |||
|---|---|---|---|---|---|---|---|
| log2 Fold Change | padj | log2 Fold Change | padj | log2 Fold Change | Padj | ||
| SLA-DQ beta1 domain | −1.36 | 4.51E-03 | −1.64 | 9.01E-04 | TND | TND | |
| MHC class II histocompatibility antigen SLA-DQA | −1.85 | 8.57E-04 | −1.19 | 3.97E-02 | TND | TND | |
| MHC class II DR-alpha | −1.62 | 5.34E-03 | TND | TND | TND | TND | |
| MHC class II histocompatibility antigen SLA-DRB1 | TND | TND | −1.20 | 4.72E-02 | TND | TND | |
| MHC class II, DO beta | TND | TND | −2.37 | 2.33E-03 | TND | TND | |
| MHC class II, DM beta | −1.67 | 1.84E-03 | −1.27 | 2.28E-02 | TND | TND | |
| SEL1L family member 3 | 1.59 | 4.11E-02 | TND | TND | TND | TND | |
| SEL1L adaptor subunit of ERAD E3 ubiquitin ligase | −2.13 | 1.43E-05 | −1.47 | 5.07E-03 | TND | TND | |
| Proteasome activator subunit 4 | −0.96 | 7.83E-03 | TND | TND | TND | TND | |
| Proteasome 26S subunit, non-ATPase 4 | TND | TND | 1.29 | 3.23E-03 | TND | TND | |
| Proteasome 26S subunit, non-ATPase 3 | 1.32 | 4.70E-03 | TND | TND | TND | TND | |
| Proteasome 26S subunit, ATPase 5 | TND | TND | 0.89 | 2.78E-02 | TND | TND | |
| Proteasome 26S subunit, ATPase 3 | TND | TND | 1.16 | 3.35E-02 | TND | TND | |
| Proteasome 26S subunit, ATPase 1 | TND | TND | 1.10 | 2.25E-02 | TND | TND | |
| Proteasome inhibitor subunit 1 | 0.98 | 3.08E-02 | 1.10 | 1.61E-02 | TND | TND | |
| Cathepsin S | −2.10 | 5.96E-06 | −1.88 | 2.60E-04 | TND | TND | |
| ADRM1 26S proteasome ubiquitin receptor | 1.20 | 1.60E-02 | TND | TND | TND | TND | |
Differentially expressed genes associated with autophagy. TND = transcript not detected
| Gene | Description | Differential expression in High dose | Differential expression in medium dose | Differential expression in Low dose | ||||
|---|---|---|---|---|---|---|---|---|
| log2 Fold Change | padj | log2 Fold Change | padj | log2 Fold Change | Padj | |||
| Autophagy related 4C cysteine peptidase | −1.39 | 1.64E-02 | TND | TND | TND | TND | ||
| Autophagy related 4D cysteine peptidase | 1.10 | 4.64E-02 | TND | TND | TND | TND | ||
| BCL2 interacting protein 3 | 3.09 | 2.93E-09 | 2.53 | 1.72E-05 | TND | TND | ||
| Dopachrome tautomerase | TND | TND | −1.94 | 4.41E-02 | TND | TND | ||
| DNA damage regulated autophagy modulator 2 | 9.44E-06 | −1.58 | 5.40E-03 | TND | TND | |||
| Ectopic P-granules autophagy protein 5 homolog | TND | TND | −1.38 | 2.98E-02 | TND | TND | ||
| FMR1 autosomal homolog 2 | TND | TND | 1.01 | 1.50E-02 | TND | TND | ||
| NBR1 autophagy cargo receptor | −1.25 | 1.41E-03 | TND | TND | TND | TND | ||
| Suppressor of glucose, autophagy associated 1 | 1.41 | 1.47E-03 | TND | TND | TND | TND | ||
| SS nuclear autoantigen 1 | 1.23 | 2.04E-02 | 1.13 | 3.81E-02 | TND | TND | ||
| FUN14 domain containing 1 | TND | TND | TND | TND | −0.96 | 3.69E-02 | ||
| Growth arrest-specific 2 like 2 | 1.26E-06 | TND | TND | TND | TND | |||
| Growth arrest specific 2 like 1 | 1.31 | 4.10E-02 | 1.39 | 2.98E-02 | TND | TND | ||
| Growth arrest specific 2 like 3 | TND | TND | 2.45E-02 | TND | TND | |||
| Growth arrest specific 7 | 1.86 | 5.02E-05 | TND | TND | TND | TND | ||
| Growth arrest specific 8 | 2.60E-15 | 1.52 | 4.38E-03 | TND | TND | |||
| Mitotic arrest deficient 1 like 1 | 2.53E-08 | TND | TND | TND | TND | |||
| Mitotic arrest deficient 1 like 2 | 1.64 | 9.99E-03 | TND | TND | TND | TND | ||
| Growth arrest and DNA damage inducible gamma | 2.25 | 1.39E-02 | 2.11 | 3.35E-02 | TND | TND | ||
| Growth arrest and DNA damage inducible beta | 1.73 | 1.33E-02 | 2.00 | 8.46E-03 | TND | TND | ||
| Fas apoptotic inhibitory molecule 2 | TND | TND | 3.96 | 2.87E-03 | TND | TND | ||
| Nuclear protein 1, transcriptional regulator | 8.83E-14 | 6.21E-15 | TND | TND | ||||
| Apoptotic peptidase activating factor 1 | 6.29E-03 | TND | TND | TND | TND | |||
Top 20 ASFV genes by counts in TPM
| Gene | Gene counts (TPM) High dose | Gene counts (TPM) Medium dose | Gene counts (TPM) Low dose |
|---|---|---|---|
| MGF 100-1 L | 862 | 2097 | 20 |
| E184L | 1004 | 1533 | 18 |
| B646L | 1001 | 1271 | 18 |
| B385R | 436 | 1185 | 18 |
| I196L | 516 | 1155 | 10 |
| MGF 360-4 L | 376 | 989 | 21 |
| NP1450L | 648 | 917 | 53 |
| MGF 360-1La_CDS | 297 | 864 | 5 |
| I215L | 369 | 781 | 73 |
| K145R | 434 | 735 | 43 |
| E301R | 313 | 719 | 10 |
| C962R | 395 | 701 | 47 |
| MGF 360-21R | 229 | 696 | 21 |
| MGF 360-6 L | 226 | 689 | 40 |
| A151R | 265 | 653 | 4 |
| M448R | 260 | 651 | 21 |
| B354L | 305 | 631 | 81 |
| CP312R | 341 | 623 | 15 |
| H339R | 259 | 588 | 16 |
| MGF 360-15R | 286 | 563 | 34 |
Fig. 4A Gene counts (in TPM) of ASFV Multigene families (MGFs), in high, medium and low dose groups, created with Datawrapper on https://www.datawrapper.de/; accessed on 2nd March 2022, (B) Venn diagram of shared DEGs in the pig host and (C) Venn diagram of shared DEGs in the ASFV pathogen
Differentially expressed ASFV genes in high and medium dose groups. TND = transcript not detected
| ORF (Gene) | Differential expression in High dose | Differential expression in medium dose | Differential expression in Low dose | Description/Function | Reference | |||
|---|---|---|---|---|---|---|---|---|
| log2 Fold Change | Padj | log2 Fold Change | padj | log2 Fold Change | padj | |||
| A151R | 2.68 | 2.74E-02 | 2.99 | 1.60E-02 | TND | TND | Inhibits Absent in Melanoma 2 (AIM2) inflammasome activation. | [ |
| A240L (TK) | 2.10 | 4.80E-02 | 2.38 | 4.63E-02 | TND | TND | Thymidylate kinase Involved viral in DNA synthesis | [ |
| B646L (p72) | 2.34 | 4.80E-02 | 2.25 | 4.76E-02 | TND | TND | Encodes the variable major capsid protein, p72, an immunogenic protein in natural infections. Involved in virion assembly and entry. Late transcription gene. | [ |
| C84L | −2.74 | 7.99E-03 | −2.82 | 8.18E-03 | TND | TND | Uncharacterised protein | [ |
| CP204L (p30) | 2.23 | 4.80E-02 | TND | TND | TND | TND | Plays a role in virus cell tropism, and is essential for effective virus entry and replication in macrophages. | [ |
| E184L (j12L) | 2.13 | 4.80E-02 | 2.25 | 4.76E-02 | TND | TND | Uncharacterised protein | |
| EP402R (CD2v) | 2.08 | 4.81E-02 | 2.28 | 4.76E-02 | TND | TND | Similar to host CD2 protein, needed for binding red blood cells to infected cells and extracellular virus particles; responsible for heamadsorption in infected cells; glycoprotein inserted into external virus envelope | [ |
| I177L (k14L) | 2.13 | 4.80E-02 | 2.61 | 3.54E-02 | TND | TND | Uncharacterised protein | [ |
| I196L (k15L) | 2.15 | 4.80E-02 | 2.37 | 4.72E-02 | TND | TND | Uncharacterised protein | [ |
| I215L (k13L) | TND | TND | 1.51 | 4.76E-02 | TND | TND | Ubiquitin-conjugating enzyme | [ |
| I73R (k10R) | 2.24 | 4.80E-02 | 2.59 | 3.54E-02 | TND | TND | Uncharacterised protein | [ |
| K78R (p10) | 2.05 | 4.97E-02 | TND | TND | TND | TND | DNA-binding protein p10 involved in morphogenesis | [ |
| MGF 100-2 L | 2.82 | 2.45E-02 | 3.22 | 1.18E-02 | TND | TND | Modulate host cell functions | [ |
| MGF 100-3 L | 2.79 | 2.45E-02 | 3.15 | 1.18E-02 | TND | TND | ||
| MGF 360-15R | 2.55 | 3.57E-02 | 2.78 | 2.79E-02 | TND | TND | ||
| MGF 360-22R | 2.21 | 4.80E-02 | 2.48 | 3.85E-02 | TND | TND | ||
| MGF 360-4 L | 2.08 | 4.81E-02 | 2.50 | 3.85E-02 | TND | TND | ||
| NP1450L (g2L) | 2.26 | 4.80E-02 | 2.28 | 4.76E-02 | TND | TND | RNA polymerase subunit 1 is involved in transcription | [ |
The KEGG significantly enriched pathways in the three infective doses (high, medium, and low)
| ID | Description | p.adjust | qvalue | Count | |
|---|---|---|---|---|---|
| High vs. control | ssc04610 | Complement and coagulation cascades | 8.42E-03 | 8.17E-03 | 12 |
| ssc05323 | Rheumatoid arthritis | 2.89E-02 | 2.80E-02 | 12 | |
| ssc04657 | IL-17 signaling pathway | 3.37E-02 | 3.27E-02 | 12 | |
| Medium vs. control | ssc04060 | Cytokine-cytokine receptor interaction | 4.12E-04 | 3.81E-04 | 24 |
| ssc05323 | Rheumatoid arthritis | 4.12E-04 | 3.81E-04 | 14 | |
| ssc04061 | Viral protein interaction with cytokine and cytokine receptor | 4.12E-04 | 3.81E-04 | 13 | |
| ssc05340 | Primary immunodeficiency | 1.37E-03 | 1.26E-03 | 9 | |
| ssc04640 | Hematopoietic cell lineage | 1.40E-03 | 1.29E-03 | 13 | |
| ssc05144 | Malaria | 1.68E-03 | 1.56E-03 | 10 | |
| ssc04080 | Neuroactive ligand-receptor interaction | 1.80E-02 | 1.66E-02 | 17 | |
| ssc04672 | Intestinal immune network for IgA production | 1.80E-02 | 1.66E-02 | 8 | |
| ssc05142 | Chagas disease | 1.80E-02 | 1.66E-02 | 13 | |
| ssc04657 | IL-17 signaling pathway | 1.80E-02 | 1.66E-02 | 11 | |
| ssc04514 | Cell adhesion molecules | 2.28E-02 | 2.11E-02 | 14 | |
| Low vs. control | ssc04610 | Complement and coagulation cascades | 5.04E-03 | 4.60E-03 | 3 |
| ssc05171 | Coronavirus disease - COVID-19 | 7.38E-03 | 6.73E-03 | 4 | |
| ssc04611 | Platelet activation | 1.38E-02 | 1.26E-02 | 3 | |
| ssc04613 | Neutrophil extracellular trap formation | 1.38E-02 | 1.26E-02 | 3 |
Fig. 5Top enriched KEGG pathways and GO annotations of the DEGs identified from the high dose group. A. Overrepresented gene ratios of significantly expressed genes activated or suppressed in the high dose group. B. Enrichment distribution of the overrepresented terms in the high dose group. C. Network of interacting genes in the top three enriched GO terms
Fig. 6Top enriched KEGG pathways and GO annotations of the common DEGs identified from the medium dose group. A. Overrepresented gene ratios of significantly expressed genes activated or suppressed in the medium dose group. B. Enrichment distribution of the overrepresented terms in the medium dose group. C. Network of interacting genes in the top three enriched GO terms color-coded by their fold change value
Fig. 7Top enriched KEGG pathways and GO annotations of the common DEGs identified from the low dose group. A. Overrepresented gene ratios of significantly expressed genes activated or suppressed in the low dose group. B. Enrichment distribution of the overrepresented terms in the low dose group. C. Network of interacting genes in the top three enriched GO terms color-coded by their fold change value